Inhibikase Therapeutics, Inc.
Public company- Headquarters
- WILMINGTON, Delaware
- Industry
- Biotechnology
- Ticker
- IKT
- CIK
- 0001750149
WARN notices since 2024
Workers affected since 2024
Executive changes, last 12 months
Last event
Workers affected over time
Cumulative workers in WARN notices since 2024
Not enough notices to chart yet.
Leadership
| Role and person | Since | Change |
|---|---|---|
| directorDennis Berman | Oct 20, 2026 | Departed |
| Class III directorScott Wasserman | Oct 20, 2026 | Appointed |
Related companies
Same industry and state, with recent events.
- ANAVEX LIFE SCIENCES CORP.
CEO appointed: Terrie Kellmeyer, Ph.D.
- RECURSION PHARMACEUTICALS, INC.
Chair of the Board appointed: Fred Hassan
- Vir Biotechnology, Inc.
Class III director appointed: Suzanne Topalian, M.D.
- AMGEN INC
director appointed: David W. Gibbs
- Executive departure
director departs: Dennis Berman
Dennis Berman, director of Inhibikase Therapeutics, Inc., resigns the role, effective October 19, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Oct 20, 2026Role: director
- Executive appointment
Class III director appointed: Scott Wasserman
Scott Wasserman was named Class III director of Inhibikase Therapeutics, Inc., effective October 19, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Oct 20, 2026Role: Class III director
Last verified Nov 9, 2026